AzurRx BioPharma Inc. AZRX Archives - Page 3 of 4

TuesdayJan 05, 2021 10:06 am

QualityStocksNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Participation in LifeSci Partners Corporate Access Event

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of nonsystemic, recombinant therapies for gastrointestinal diseases, will be participating in the 10th annual LifeSci Partners Corporate Access Event. As part of the company’s participation, AzurRx president and CEO James Sapirstein will present a summary of the company’s business and clinical-development programs to any interested parties. His presentation will also include expected 2021 highlights. In addition, Sapirstein will participate in virtual one-on-one meetings with registered investors and pharmaceutical companies. The multiday event is scheduled for Jan. 6–8 and 11–14, 2021. To register for the event, visit https://ibn.fm/JBmMH To view the full press release, visit…

MondayJan 04, 2021 12:02 pm

QualityStocksNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Worldwide License Agreement with First Wave Bio, $8M Offerings

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal (“GI”) diseases, today announced its entry into an exclusive worldwide licensing agreement with First Wave Bio Inc. for the use of its patented and proprietary oral and rectal formulations of niclosamide for the treatment of immune checkpoint inhibitor-associated colitis (“ICI-AC”) and COVID-19 GI infections. “The acquisition of rights to niclosamide for these indications gives us an opportunity to strategically expand our existing pipeline and pursue multiple GI indications in the oncology and infectious disease arenas,” said James Sapirstein, president and CEO of AzurRx. “We are…

TuesdayDec 22, 2020 2:28 pm

QualityStocksNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Aims to Identify Best Delivery Method for Lead Drug Candidate

AzurRx BioPharma (NASDAQ: AZRX), a clinical-stage biopharmaceutical company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, recently submitted a protocol amendment request to the U.S. Food and Drug Administration (“FDA”). Approval of the amendment will allow AzurRx to modify its current Phase 2b OPTION 2 trial of MS1819 in cystic fibrosis (“CF”) patients to add a study arm that uses immediate release capsules (https://ibn.fm/SxH8F). The existing study arm uses delayed release capsules, so the expansion will allow AzurRx to compare data from both arms to determine the best delivery method for its lead product, an exocrine pancreatic…

FridayDec 11, 2020 2:34 pm

QualityStocksNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Advancing MS1819 in Fight to Improve Treatment of EPI in CF, CP Patients

AzurRx BioPharma (NASDAQ: AZRX) is focused on the development of its lead drug candidate, MS1819, for exocrine pancreatic insufficiency (“EPI”) in patients suffering from cystic fibrosis (“CF”) and chronic pancreatitis (“CP”). While CF is a relatively rare genetic disease, innovative and effective therapies are needed. CF is a dangerous condition that affects multiple body functions and organs, putting patients at risk of developing severe life-threatening illnesses. Technological advances have greatly increased the life span for CF patients. While children with CF rarely made it to elementary school age in the 1950s, the median age of survival for a CF patient…

MondayNov 30, 2020 10:57 am

QualityStocksNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Advancement of MS1819 Combination Therapy Trial in Turkey

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that the first two patients have been dosed in Turkey for its Phase 2 trial. The trial evaluates its investigational drug, MS1819, in combination with the current standard of care, porcine-derived pancreatic enzyme replacement therapy (“PERT”), for the treatment of severe exocrine pancreatic insufficiency (“EPI”) in patients with cystic fibrosis (“CF”). “In the midst of a global pandemic and unpredictable obstacles, we are very encouraged to see our combination therapy trial moving forward at one of the clinical testing sites in Turkey,”…

WednesdayNov 25, 2020 10:45 am

AzurRx BioPharma Inc. (NASDAQ: AZRX) Planning to Test Immediate Release MS1819 Capsules in Cystic Fibrosis Study

The company plans to add another study arm to its ongoing Phase 2b OPTION 2 clinical study which currently tests delayed release capsules If it receives FDA approval, AzurRx would be able to identify the optimal delivery method for its drug candidate MS1819 without significant extra costs or delays Enrollment in this arm of the study could begin as early as December 2020 AzurRx BioPharma (NASDAQ: AZRX), a clinical-stage biopharmaceutical company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, has submitted a protocol amendment request to the U.S. Food and Drug Administration that would allow it to test immediate…

TuesdayNov 24, 2020 1:49 pm

QualityStocksNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Featured in Stock2Me Podcast

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, was featured in InvestorBrandNetwork’s (“IBN”) latest episode of its Stock2Me Podcast. Stock2Me Podcasts feature a fascinating array of companies and individuals, many of whom are revolutionizing business practices within their respective markets. AZRX president and CEO James Sapirstein joins IBN’s Stuart Smith in the latest episode to discuss how AzurRx is working to redefine the standard of care for patients living with cystic fibrosis and chronic pancreatitis. “AzurRx Bio has been around for five years. … Our main product, MS1819, is being studied in…

FridayNov 20, 2020 11:01 am

QualityStocksNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Featured in Simply Wall St Article

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, was featured in a recent Simply Wall St article. The piece, titled “Is AzurRx BioPharma (NASDAQ:AZRX) In A Good Position To Invest In Growth?,” explores the rate of the company’s annual negative free cash flow (“cash burn”) and whether it should be concerning to shareholders. The article reads, “Even though its cash burn relative to its market cap makes us a little nervous, we are compelled to mention that we thought AzurRx BioPharma's cash burn reduction was relatively promising. Even though we don't think…

TuesdayNov 17, 2020 2:53 pm

AzurRx BioPharma Inc. (NASDAQ: AZRX) Making Strides with MS1819 Clinical Trials for Cystic Fibrosis-Associated Pancreatic Insufficiency

Globally it is estimated that 70,000 people suffer from CF, with half the population in the United States The global CF therapeutics market size was valued at $4.62 billion in 2018 and is expected to reach an estimated $9.3 billion by 2026 AzurRx BioPharma’s MS1819, currently undergoing clinical trials, is a promising therapy for severe exocrine pancreatic insufficiency in patients with cystic fibrosis While still a relatively rare genetic disease, cystic fibrosis (“CF”) remains a dangerous condition that affects multiple body functions and organs, putting patients at risk of developing severe life-threatening illnesses. This is why the need for innovative…

TuesdayNov 17, 2020 12:48 pm

QualityStocksNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Requests Protocol Amendment to Phase 2b Study to Add Study Arm

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of nonsystemic, recombinant therapies for gastrointestinal diseases, will be submitting a protocol amendment request to the U.S. Food and Drug Administration (“FDA”) for its Phase 2b OPTION 2 trial of MS1819 for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis. The proposed amendment requests the potential to add a study arm that uses an immediate-release MS1819 capsule. If approved, AZRX will be able to compare data from the existing arm that uses enteric (delayed-release) capsules with data from the new arm. Everything else regarding the study, including trial objectives, endpoints and…

Site Search

Company Search

Tag: AzurRx BioPharma Inc. AZRX